UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices and zip code)
Registrant’s
telephone number, including area code: |
(Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
By letter dated September 2, 2022, Jeff Dyer, PhD, a director of PolarityTE, Inc. (the “Company”), notified the Company of his decision to resign from the Board of Directors, effective immediately. A copy of the press release announcing the foregoing is furnished as Exhibit 99.1 hereto.
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits. |
Exhibit No. |
Description | |
99.1 | Press Release dated September 8, 2022, titled “PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors.” | |
104 | Cover Page Interactive Data File, formatted in Inline XBRL |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
POLARITYTE, INC. | |
Dated: September 8, 2022 | /s/ Jacob Patterson |
Jacob Patterson | |
Chief Financial Officer |
Exhibit 99.1
PolarityTE Announces Resignation of Jeff Dyer from its Board of
Directors
SALT LAKE CITY, September 8, 2022 – PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately.
“On behalf of our Board and PolarityTE’s management team, we thank Jeff for his service and longstanding commitment to the Company,” stated Richard Hague, Chief Executive Officer of PolarityTE. “We greatly appreciate the leadership and insight that Jeff has provided over the past five and a-half years as we pursued the path that led to an IND accepted by FDA for our product SkinTE® and the start of an approved clinical trial in diabetic foot ulcers.”
Dr. Dyer stated, “It has been an honor to serve as a director of PolarityTE. Richard and his team have done an incredible job advancing PolarityTE’s IND application and clinical trial process. Now that PolarityTE has settled into a well-defined regulatory path and clinical trial process for SkinTE®, I believe my time and talents may be better applied in other opportunities and endeavors.” Dr. Dyer went on to say, “I want to thank my fellow directors and wish the Company nothing but success.”
About PolarityTE®
PolarityTE, Inc., headquartered in Salt Lake City, Utah, is a biotechnology company developing regenerative tissue products. PolarityTE’s first regenerative tissue product is SkinTE®. PolarityTE has an open investigational new drug application (IND) for SkinTE® with the U.S. Food and Drug Administration (FDA) and is now pursuing the first of two pivotal studies on SkinTE® needed to support a biologics license application (BLA). SkinTE® is available for investigational use only. Learn more at www.PolarityTE.com.
Forward Looking Statements
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as “believes,” “may,” “expects,” “anticipates,” “intend,” “plan,” “will,” “would,” “should” and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company’s beliefs and assumptions as of the date of this release. The Company’s actual results could differ materially due to the impact of the COVID-19 pandemic, future clinical studies, and FDA regulatory matters, which cannot be predicted, and the risk factors and other items described in more detail in the “Risk Factors” section of the Company’s Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES SELF and WELCOME TO THE SHIFT are registered trademarks of PolarityTE, Inc.
CONTACTS
Investors:
PolarityTE Investor Relations
ir@PolarityTE.com
385-831-5284
Media:
David Schull or Ignacio Guerrero-Ros
David.schull@russopartnersllc.com
Ignacio.guerrero-ros@russopartnersllc.com
Cover |
Sep. 02, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Sep. 02, 2022 |
Entity File Number | 001-32404 |
Entity Registrant Name | POLARITYTE, INC. |
Entity Central Index Key | 0001076682 |
Entity Tax Identification Number | 06-1529524 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 1960 S. 4250 West |
Entity Address, City or Town | Salt Lake City |
Entity Address, State or Province | UT |
Entity Address, Postal Zip Code | 84104 |
City Area Code | (800) |
Local Phone Number | 560-3983 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, Par Value $0.001 |
Trading Symbol | PTE |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
-8?20$3;8T.P6BP^0"X99K>]9!:G
7)>?1>
MQNV1F,JWT6>2TO/H Q54$2/5V^@KX9G;(H>,4Q4-9+K@U%#[1='P>?2FTWL3
M1^TVH-ZO5"12?7D8;>N=&[/0Y]WN
*0K M@I?% &*0^.#^D8A,(:*,%UTCWS=V@WN%;7%-^Z7>PVKW?(_4$L! A0# M% @ RT,H5?K3Q[)>"0 N#( H ( ! &5X.3DM M,2YH=&U02P$"% ,4 " #+0RA5H*^?G-41 #7B@ "P M@ &&"0 9F]R;3@M:RYH=&U02P$"% ,4 " #+0RA5^Z&UNU # "\# M$ @ &$&P <'1E+3(P,C(P.3 R+GAS9%!+ 0(4 Q0 ( M ,M#*%5Q.Z;0_@H ("& 4 " 0(? !P=&4M,C R,C Y M,#)?;&%B+GAM;%!+ 0(4 Q0 ( ,M#*%50CC^ 50< -A7 4 M " 3(J !P=&4M,C R,C Y,#)?<')E+GAM;%!+!08 !0 % #,! ( "Y,0 ! end